Evidence map›Paper›PMID 31104009›Full record

ArticleCancer biomarkers : section A of Disease markers2019

Using tRNA halves as novel biomarkers for the diagnosis of gastric cancer.

Linwen Zhu, Tianwen Li, Yijing Shen, Xiuchong Yu, Bingxiu Xiao, Junming Guo

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer biomarkers : section A of Disease markers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Emerging roles of tRNA-derived small RNAs in cancer biology.Experimental & molecular medicine · 2023
    Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. tRNA-derived fragments in gastric cancer: Biomarkers and functions.Journal of cellular and molecular medicine · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Linwen ZhuDepartment of Biochemistry and Molecular Biology, and Zhejiang Key Laboratory of Pathophysiology, Medical School of Ningbo University, Ningbo, Zhejiang 315211, China.
Tianwen LiDepartment of Biochemistry and Molecular Biology, and Zhejiang Key Laboratory of Pathophysiology, Medical School of Ningbo University, Ningbo, Zhejiang 315211, China.
Yijing ShenDepartment of Biochemistry and Molecular Biology, and Zhejiang Key Laboratory of Pathophysiology, Medical School of Ningbo University, Ningbo, Zhejiang 315211, China.
Xiuchong YuDepartment of Gastrointestinal Surgery, Ningbo No. 1 Hospital and the Affiliated Hospital of Medical School of Ningbo University, Ningbo, Zhejiang 315010, China.
Bingxiu XiaoDepartment of Biochemistry and Molecular Biology, and Zhejiang Key Laboratory of Pathophysiology, Medical School of Ningbo University, Ningbo, Zhejiang 315211, China.
Junming GuoDepartment of Biochemistry and Molecular Biology, and Zhejiang Key Laboratory of Pathophysiology, Medical School of Ningbo University, Ningbo, Zhejiang 315211, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundtRNA halves (tiRNAs) are produced from mature tRNAs. They have important roles both with in normal cells and cancer cells. However, the diagnostic value of tiRNAs in cancers have not yet been elucidated.

objectiveTo explore the diagnostic value of tiRNA-5034-GluTTC-2 in gastric cancer. PATIENTS AND

methodsQuantitative reverse transcription-polymerase chain reaction was used to detect the expression levels of tiRNA-5034-GluTTC-2 in paired gastric cancer tissues and adjacent normal tissues, plasmas from patients with gastric cancer and healthy people, and gastric cancer cell lines. Then, the relationship between its levels and clinicopathological factors of patients with gastric cancer was analyzed. A receiver operating characteristic (ROC) curve was established to predict the diagnostic value.

resultstiRNA-5034-GluTTC-2 was first found to be down-regulated in gastric cancer tissues and plasmas. Its levels were significantly associated with tumor size. The area under the ROC curve (AUC) was 0.779 and 0.835 in tissue and plasma, respectively. The sensitivity, specificity and AUC were 84.7%, 92.8%, and 0.915 when tissues and plasmas were used in combination, respectively. The overall survival rate of patients with a lower expression of tiRNA-5034-GluTTC-2 was significantly lower than those with a higher expression.

conclusionsThese results indicated that tiRNA-5034-GluTTC-2 may be a novel biomarker for the diagnosis of gastric cancer.

Indexed as

Biomarkers, TumorAdultAgedCell Line, TumorCloning, MolecularFemaleGene ExpressionHumansMaleMiddle AgedNeoplasm GradingNeoplasm MetastasisNeoplasm StagingProportional Hazards ModelsRNA, TransferROC CurveBiomarkers, TumorRNA, Transferbiomarkerdiagnosisgastric cancertiRNA-5034-GluTTC-2tRNA halves

Identifiers

PMID31104009
PMCPMC13082404

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.